All In Biotech

Drug Trial Radar · NCT03128138

Single Ascending Dose Study of Safety and Tolerability of SPH3127 Tablet in Chinese Healthy Volunteers

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Describe Pharmacokinetics/Pharmacodynamics, and the Safety and of SPH3127 Tablet in Chinese Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Oct 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Dec 1, 2016

Primary completion

Jun 30, 2018

Study completion Jul 30, 2018

Sponsor

Sponsor type
Industry
First posted
Apr 25, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

1. To evaluate safety, tolerability and pharmacokinetics (PK) and pharmacodynamics (PD) characteristics of SPH3127 dose escalation, a single oral dose in Chines healthy volunteers. 2. To explore the appropriate dose and provide the basis for the subsequent clinical trials.

Conditions

  • Hypertension

Interventions

  • SPH3127Drug

    Drug: SPH3127 Tablet Drug: Placebo Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of safety parameters [adverse events, laboratory data, vital signs, and ECG]Time frame: 10 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The capital medical university affiliated Beijing anzhen hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.